Mainz Biomed to Present at the H.C. Wainwright Bioconnect Virtual Conference
BERKELEY, Calif. and MAINZ, Germany, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief Executive Officer, will present at the H.C. Wainwright Bioconnect Virtual Conference taking place on January 10-13, 2022.
To access Mainz’s presentation at the H.C. Wainwright Bioconnect Virtual Conference, please visit www.hcwevents.com/bioconnect to register for the event.
About Colorectal Cancer
About Mainz Biomed N.V.
For more information, please visit www.mainzbiomed.com
For media enquiries, please contact [email protected]
For investor enquiries, please contact [email protected]
Welcome Reception - For Paid Conference Pass Holders, Exhibitors, Sponsors, Speakers, Press
Lessons in Localization â€“ Retail
Future of Work #TECHSUPERSHOW Expo Hall Open